Clover Biopharmaceuticals Ltd (2197)

Hong Kong
Currency in HKD
0.26
-0.01(-3.77%)
Delayed Data·

HK:2197 Financials

Key Ratios

P/E Ratio-0.26
Price/Book-0.15
Debt / Equity-5.48%
Return on Equity76.27%
Dividend Yield0.00%
EBITDA-926.43M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa38.42
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa-672.94
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa-954.84
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa-903.43
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa812.74
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa1,907.66
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa-1,636.3
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa225.07
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa-288.49
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa3.17
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa-51.5
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa-334.62
* In Millions of CNY (except for per share items)

Earnings

Latest Release
Apr 17, 2025
EPS / Forecast
-0.64 / --
Revenue / Forecast
48.52M / --
EPS Revisions
Last 90 days

FAQ

What were Clover Biopharmaceuticals's earnings for the latest quarter?

The Clover Biopharmaceuticals EPS (TTM) is -0.72. Clover Biopharmaceuticals reported sales of 48.52, net income of -808.31, and EPS of -0.64 for the latest quarter.

What was Clover Biopharmaceuticals's net income for the latest quarter?

Clover Biopharmaceuticals's net income for the latest quarter was -808.31.

How did Clover Biopharmaceuticals's performance compare year-over-year in the latest quarter?

The company's revenue moved from -10.10 in the previous quarter to 48.52 in the latest quarter, and net income moved from -95.12 to -808.31 compared to the previous quarter.

What is Clover Biopharmaceuticals's net profit margin on a TTM basis?

Clover Biopharmaceuticals's trailing twelve months (TTM) net profit margin is -2,351.51%.

How does Clover Biopharmaceuticals's debt to equity ratio compare to industry standards?

Clover Biopharmaceuticals's total debt-to-equity ratio is -5.48%.

What is Clover Biopharmaceuticals's return on investment on a TTM basis?

Clover Biopharmaceuticals's trailing twelve months (TTM) return on investment (ROI) is 76.27%.

Did Clover Biopharmaceuticals gain or lose cash last quarter?

In the latest quarter, Clover Biopharmaceuticals's net change in cash was -57.53 million.

What were Clover Biopharmaceuticals's total assets and liabilities in the latest quarter?

As of the latest quarter, Clover Biopharmaceuticals reported total assets of 812.74 million and total liabilities of 1,907.66 million.

How has Clover Biopharmaceuticals's total revenue grown this year?

Clover Biopharmaceuticals's total revenue was -10.10 in the previous quarter and 48.52 in the latest quarter.

What is Clover Biopharmaceuticals's gross margin on a TTM basis?

Clover Biopharmaceuticals's trailing twelve months (TTM) gross margin is -1,751.59%.

What was Clover Biopharmaceuticals's revenue per share for the latest quarter?

Clover Biopharmaceuticals's revenue per share for the latest quarter was 12.13.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.